Sp191
THE EMERGING ROLE OF MULTI-OMICS IN PERSONALIZING IBD THERAPY
Date
May 18, 2024
Explore related products in the following collection:
Presenter
University Hospitals Leuven
Tracks
Related Products
VEDOLIZUMAB REDUCES IGG+ PLASMA CELLS AND FCγR SIGNALLING IN TREATMENT RESPONDERS
Vedolizumab (VDZ) is a monoclonal antibody that targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC) and Crohn’s disease, its mode of action (MOA) remains unclear…
THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN
Background: Although the precise role of eosinophils in IBD is debated, elevated eosinophils may influence response to therapy and clinical outcomes1. Thus, therapeutic agents which affect both neutrophil and eosinophil recruitment may provide more robust clinical improvement in patients with UC…
Insights into IBD Biology From Single-Cell Sequencing
(WITHDRAWN) SINGLE CELL ANALYSIS OF GUT BIOPSY TISSUE REVEALS CELL TYPE- AND INFLAMMATION-SPECIFIC EXPRESSION QUANTATIVE TRAIT LOCI IN CROHN'S DISEASE
